The effect of liraglutide on endothelial function in patients with type 2 diabetes

What Was Tested

The paper reports a study of Glucagon and Liraglutide, published as a randomized controlled trial.

This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease.

At baseline and Week 12, venous occlusion plethysmography was used to measure forearm blood flow (FBF) in response to acetylcholine (ACh) and sodium nitroprusside (SNP) before and after (L)-N(G)-monomethyl arginine (L-NMMA) infusion.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Patients were randomized to liraglutide, placebo or glimepiride.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

What Was Measured

This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease.

At baseline and Week 12, venous occlusion plethysmography was used to measure forearm blood flow (FBF) in response to acetylcholine (ACh) and sodium nitroprusside (SNP) before and after (L)-N(G)-monomethyl arginine (L-NMMA) infusion.

Topics PubMed links to this paper include Acetylcholine, Blood Glucose, Blood Pressure, C-Peptide, Diabetes Mellitus, Type 2, Endothelium, Vascular and Glucagon.

Author keywords: Glucagon-like peptide-1, endothelial function and liraglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Liraglutide.

The publication is from 2014 (Diabetes & vascular disease research), a journal based in England.

More context: the Glucagon compound page and the Liraglutide compound page.